Spinal surgery
Conditions
Interventions
Conventional induction dose group:0.6mg/kg rocuronium was given intravenously
Group M :0.9mg/kg rocuronium was given intravenously
Group H :1.2mg/kg rocuronium was given intravenously
Sponsors
Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: American Society of Anesthesiologists (ASA) physical status II–III;18-75 years; body mass index between 18 and 40 kg/m^2.
Exclusion criteria
Exclusion criteria: 1. Suffering from severe heart, lung, liver or kidney dysfunction; unable to speak or understand the doctor's instructions; 2. Can not cooperate; participate in other medical trials; pregnancy; with porphyria; allergic to the drugs used in the trial; 3. Daily use of strong opioids (morphine, oxycodone, methadone, fentanyl or ketobemidone); alcohol or drug abuse; refusal to sign informed consent; central nervous system disease or neuropsychiatric disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| visual analogue scale (VAS) for pain at rest in 7 days after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| effect of rocuronium bromide on muscle relaxation;intraoperative hemodynamic parameters;the opioid drug demands and doses delivered by nurses in the first 7 days after surgery;SRS surgical satisfaction score;Incidence of perioperative adverse events;hospital length of stay;rate of 30-day readmission; | — |
Countries
China
Contacts
Public ContactWang Zhiping
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed